Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:55:20 EST Mon 12 Jan 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:SRRK - SCHOLAR ROCK HOLDING CORPORATION - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SRRK - Q0.540.52·48.680.143.56+1.383.31,147.747,93512,53242.455  43.66  40.62548.28  22.7116:20:0007:0015 min RT 2¢

Recent Trades - Last 10 of 12532
Time ETExPriceChangeVolume
16:20:00Q43.561.38654
16:10:04Q43.561.381
16:10:04Q43.561.381
16:04:45Q43.561.381
16:04:42Q43.561.381
16:04:25Q43.561.381
16:04:12Q43.561.381
16:04:06Q43.561.381
16:04:03Q43.561.381
16:02:09Q43.561.381,397

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-12 07:00U:SRRKNews ReleaseScholar Rock Highlights 2026 Strategic Priorities
2026-01-05 08:00U:SRRKNews ReleaseScholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-13 10:57U:SRRKNews ReleaseScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-18 08:00U:SRRKNews ReleaseScholar Rock to Present at Upcoming Investor Conferences
2025-11-14 07:00U:SRRKNews ReleaseScholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
2025-11-12 16:15U:SRRKNews ReleaseScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-04 08:00U:SRRKNews ReleaseScholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
2025-10-23 08:00U:SRRKNews ReleaseScholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
2025-10-17 16:15U:SRRKNews ReleaseScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-23 07:00U:SRRKNews ReleaseFDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
2025-09-12 16:15U:SRRKNews ReleaseScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-15 16:15U:SRRKNews ReleaseScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-14 08:00U:SRRKNews ReleasePivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
2025-08-06 07:00U:SRRKNews ReleaseScholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
2025-07-21 08:00U:SRRKNews ReleaseScholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025
2025-07-18 16:15U:SRRKNews ReleaseScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-23 08:00U:SRRKNews ReleaseScholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
2025-06-18 07:00U:SRRKNews ReleaseScholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
2025-06-13 16:15U:SRRKNews ReleaseScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-05 08:00U:SRRKNews ReleaseScholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference